{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:26:49Z","timestamp":1771064809499,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"U.S. Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement"},{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.amepre.2018.08.016","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T03:04:45Z","timestamp":1542596685000},"page":"8-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016"],"prefix":"10.1016","volume":"56","author":[{"given":"Sabrina A.","family":"Assoumou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abriana","family":"Tasillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golnaz","family":"Eftekhari Yazdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Strick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.amepre.2018.08.016_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.amepre.2018.08.016_bib0002","first-page":"27","article-title":"Impact of new therapeutics for hepatitis C virus infection in incarcerated populations","volume":"21","author":"Spaulding","year":"2013","journal-title":"Top Antivir Med"},{"issue":"2","key":"10.1016\/j.amepre.2018.08.016_bib0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/003335491412900213","article-title":"Hepatitis C seroprevalence among prison inmates since 2001: still high but declining","volume":"129","author":"Varan","year":"2014","journal-title":"Public Health Rep"},{"issue":"6","key":"10.1016\/j.amepre.2018.08.016_bib0004","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.2105\/AJPH.2014.301943","article-title":"Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004\u20132012: limitations of 1945\u20131965 birth cohort screening in correctional settings","volume":"104","author":"Larney","year":"2014","journal-title":"Am J Public Health"},{"issue":"10","key":"10.1016\/j.amepre.2018.08.016_bib0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1377\/hlthaff.2016.0296","article-title":"New hepatitis C drugs are very costly and unavailable to many state prisoners","volume":"35","author":"Beckman","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"10.1016\/j.amepre.2018.08.016_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2105\/AJPH.2014.302071","article-title":"Survey of U.S. correctional institutions for routine HCV testing","volume":"105","author":"Beckwith","year":"2015","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.amepre.2018.08.016_bib0007","doi-asserted-by":"crossref","first-page":"134","DOI":"10.24875\/AIDSRev.M17000006","article-title":"HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community's infections","volume":"19","author":"Spaulding","year":"2017","journal-title":"AIDS Rev"},{"issue":"2","key":"10.1016\/j.amepre.2018.08.016_bib0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.idc.2018.02.014","article-title":"Five questions concerning managing hepatitis C in the justice system: finding practical solutions for hepatitis C virus elimination","volume":"32","author":"Spaulding","year":"2018","journal-title":"Infect Dis Clin North Am"},{"issue":"20","key":"10.1016\/j.amepre.2018.08.016_bib0009","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amepre.2018.08.016_bib0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11524-015-9953-4","article-title":"A budget impact analysis of newly available hepatitis C therapeutics and the financial burden on a state correctional system","volume":"92","author":"Nguyen","year":"2015","journal-title":"J Urban Health"},{"key":"10.1016\/j.amepre.2018.08.016_bib0011","series-title":"Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report","year":"2016"},{"key":"10.1016\/j.amepre.2018.08.016_bib0012","unstructured":"Nisen M. AbbVie Wages HCV drug-price war on Gilead. BloombergGadfly. August 7, 2017. https:\/\/www.bloomberg.com\/opinion\/articles\/2017-08-07\/abbvie-mavyret-price-threatens-gilead-hepatitis-dominance. Accessed November 8, 2018."},{"issue":"suppl 2","key":"10.1016\/j.amepre.2018.08.016_bib0013","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/cid\/cit300","article-title":"Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention","volume":"57","author":"Page","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"RR-4","key":"10.1016\/j.amepre.2018.08.016_bib0014","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.amepre.2018.08.016_bib0015","unstructured":"Washington State Department of Health. Viral Hepatitis C in Washington State. www.doh.wa.gov\/DataandStatisticalReports\/DiseasesandChronicConditions\/ChronicHepatitisSurveillance. Accessed June 13, 2017."},{"issue":"1","key":"10.1016\/j.amepre.2018.08.016_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.amepre.2018.08.016_bib0017","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.amepre.2018.08.016_bib0018","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-159-5-201309030-00021","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection","volume":"159","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amepre.2018.08.016_bib0019","unstructured":"Bureau of Justice Statistics. HIV in Prisons, 2015-Statistical Tables.www.bjs.gov\/content\/pub\/pdf\/hivp15st_sum.pdf. Accessed November 8, 2017."},{"issue":"2","key":"10.1016\/j.amepre.2018.08.016_bib0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of hepatitis C by screening and treatment in U.S. prisons","volume":"164","author":"He","year":"2016","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.amepre.2018.08.016_bib0021","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJMp1705991","article-title":"A tale of two epidemics\u2013HCV treatment among Native Americans and Veterans","volume":"377","author":"Reilley","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amepre.2018.08.016_bib0022","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2105\/AJPH.2004.056291","article-title":"A missed opportunity: hepatitis C screening of prisoners","volume":"95","author":"Macalino","year":"2005","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.amepre.2018.08.016_bib0023","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"Grebely","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.amepre.2018.08.016_bib0024","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/0033354916662212","article-title":"Performance of risk-based and birth-cohort strategies for identifying hepatitis C virus infection among people entering prison, Wisconsin, 2014","volume":"131","author":"Stockman","year":"2016","journal-title":"Public Health Rep"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718322219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718322219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T03:23:45Z","timestamp":1545017025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379718322219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0749379718322219"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2018.08.016","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2018.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}